With a commitment to listen to women to
understand their health needs and provide the solutions that are so
urgently needed
Organon (NYSE: OGN) has today launched as the only global health
company of its size, with a singular vision: to make a better and
healthier every day for every woman. With a majority-female
Leadership Team, the company will be headquartered in the US, with
offices across the globe including one in Shoreditch, London.
Organon has more than 60 products across an international footprint
that will serve people in more than 140 countries, with nearly 80%
of its approximately $6.5 billion in annual revenue generated
outside the U.S.
“It’s exciting to take the helm in a new and vibrant company
with such a strong purpose; a commitment to improving health
outcomes for women,” said Simon Nicholson, Managing Director of
Organon UK&ENI Cluster (UK, Ireland, Israel, Sweden, Denmark,
Norway, Finland, Latvia, Lithuania, Estonia & Iceland). “New
acquisitions and partnerships will help Organon expand beyond our
core strengths in contraceptives and fertility to meet the health
needs of women at all stages of her life. This will be fueled by a
refreshed focus on our women’s health portfolio, further biosimilar
launches, and a renewed energy put behind our trusted dermatology,
pain, respiratory and cardiovascular brands.”
“Our strength will come not only from our medicines and
solutions but from the diverse team of Organon Founders we have
gathered to launch this unique company. We are all personally
invested in this opportunity and what we do really matters.”
Diverse Portfolio will Drive Sustained Growth: Organon
will be exploring new opportunities and partnerships across its
three main pillars: women’s health, biosimilars and established
brands:
- Women’s Health: Organon has a dedicated team focusing on
improving access to contraceptive and fertility products, and a
comprehensive education and training programme to help women and
healthcare professionals understand the choices available to them.
There is a continued shift toward long-acting reversible
contraceptives (LARCs) and a large fertility market with untapped
potential driven by changing social demographics.
- Biosimilars: Building on our current growth business,
this is a dynamic market with multiple launch opportunities in the
coming years. A core area of growth with the potential to deliver
value to both Organon, the NHS and patients in the UK.
- Established Brands: The Established Brands portfolio
will be reinvigorated to maximise market-leading, well-known brands
that span key therapy areas such as cardiovascular, respiratory,
pain, bone and dermatology.
Women at the Centre: Organon’s Approach to Innovation:
Organon’s R&D philosophy is to build a business around patient
needs, with the goal of identifying and advancing healthcare
options for women that enable them to live their best lives every
day.
The company’s extensive global capabilities in clinical
development and patient safety, regulatory and medical affairs make
it well-positioned to identify promising drugs, diagnostics, and
devices with the greatest potential to impact women’s health.
“For far too long women have been told to accept many common
conditions, such as heavy, painful, and irregular menstrual
bleeding, incontinence and menopause,” said Irina Spirieva,
Commercial Operations Lead, Organon UK&ENI. “Organon’s mission
is to change this. We believe that by identifying diseases earlier
and modifying the course of diseases or health conditions, we can
improve the quality of life for women at every stage of their
lives.”
To mark the first day of trading, Organon gathered hundreds of
voices from around the world to create the “Wall of Voices,” a
multimedia installation outside the New York Stock Exchange, that
symbolises Organon’s commitment to listening to the needs and
challenges of women. The “Wall of Voices” shares powerful
perspectives, voices, and images of women highlighting the health
issues that are important to them.
Anne Connolly, Women’s Health Lead at the Royal College of
General Practitioners, is featured on the Wall of Voices: “The part
that is overlooked is that women require personalised holistic care
and her needs change during her life course. There is a lack of
recognition of the impact her pregnancy, menstrual concerns,
menopause symptoms may have not just on her physical wellbeing, but
her psychological, sexual and social functioning.”
The “Wall of Voices” installation will be available at
HereForHerHealth.com. Women around the world can add their voices
by taking the mic at HereForHerHealth.com.
To learn more about Organon, please visit organon.com.
About Organon
Organon (NYSE: OGN) is a global healthcare company formed
through a spinoff from Merck to focus on improving the health of
women throughout their lives. Here for her health, the company has
a portfolio of more than 60 medicines and products across a range
of therapeutic areas. Led by the reproductive health portfolio
coupled with an expanding biosimilars business and stable franchise
of established medicines, Organon’s products produce strong cash
flows that will support investments in future growth opportunities
in women’s health, including business development. In addition,
Organon is pursuing opportunities to collaborate with
biopharmaceutical innovators looking to commercialize their
products by leveraging its scale and presence in fast growing
international markets.
Organon has a global footprint with significant scale and
geographic reach, world-class commercial capabilities, and
approximately 9,000 employees with headquarters located in Jersey
City, New Jersey.
For more information, visit www.organon.com and connect with us
on LinkedIn and Instagram.
Forward-Looking Statement of Organon & Co., Jersey City,
N.J., USA
This news release of Organon & Co., Jersey City, N.J., USA
(the “company”) may include “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the recent global outbreak of novel coronavirus
disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing
difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of
the company’s patents and other protections for innovative
products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s filings
with the Securities and Exchange Commission (SEC) available at the
SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210602006079/en/
Media Contact: Priya Lakhani-Quiling
Priya.lakhani-quiling@organon.com Tel: +44 (0) 7957 234632 / +44
(0) 7812 743 644
Orogen Royalties (TSXV:OGN)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
Orogen Royalties (TSXV:OGN)
Historical Stock Chart
Von Nov 2023 bis Nov 2024
